A patient with relapsed blood cancer, having exhausted chemotherapy, targeted tablets, and even a stem cell transplant, used to hear the same grim sentence from Indian oncologists: "we have tried everything." Today, that sentence is changing. A single infusion of the patient's own re-engineered immune cells, manufactured in a Mumbai laboratory rather than imported from abroad, is now curing some of these patients outright. This is CAR-T cell therapy, and India's homegrown version, NexCAR19, has made a treatment that costs over ₹3 crore internationally available for a fraction of that price to Indian families.
This guide explains what CAR-T therapy actually is, who in India qualifies for it, what it costs, which hospitals offer it, and what patients and families should realistically expect from treatment and recovery.
What Is CAR-T Cell Therapy?
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is a form of immunotherapy that reprogrammes a patient's own immune cells to hunt down and destroy cancer cells. Unlike chemotherapy, which attacks rapidly dividing cells throughout the body, CAR-T therapy is a "living drug" tailored specifically to the individual patient.
How the Treatment Works
The process happens in five broad steps:
- Collection: T-cells (a type of white blood cell that normally fights infection) are collected from the patient's blood through a process called leukapheresis.
- Engineering: In a specialised laboratory, these T-cells are genetically modified to express a chimeric antigen receptor on their surface. This receptor is designed to recognise a specific protein marker, most commonly CD19, found on the surface of certain blood cancer cells.
- Expansion: The engineered cells are multiplied in the lab until there are enough to mount a meaningful attack, often tens to hundreds of millions of cells.
- Conditioning chemotherapy: Before the CAR-T cells are infused back, the patient receives a short course of low-dose chemotherapy to reduce existing immune cells and make room for the new ones to expand.
- Infusion: The engineered CAR-T cells are infused back into the patient's bloodstream, where they multiply further, seek out cells carrying the CD19 marker, and destroy them.
Once inside the body, CAR-T cells can persist for months or years, in some cases offering ongoing surveillance against cancer recurrence, similar to how a vaccine trains the immune system to recognise future threats.
India's Own CAR-T Therapy: NexCAR19
Until October 2023, this technology existed almost exclusively in the United States, Europe, and a handful of hospitals elsewhere, with price tags that put it entirely out of reach for Indian patients. That changed with the approval of NexCAR19, developed by ImmunoACT, a company spun out of IIT Bombay in partnership with the Tata Memorial Centre.
Why NexCAR19 Matters for India
- It is India's first indigenously developed and approved CAR-T cell therapy, cleared by the Central Drugs Standard Control Organization (CDSCO).
- It brings a treatment that costs US $400,000 or more in the United States down to a fraction of that price when manufactured domestically.
- It reduces India's dependence on importing complex biologic therapies, and reflects a broader push, including the government's newly announced Biopharma Shakti scheme, to build indigenous capacity in advanced cancer and autoimmune therapies.
- It has already been used in hundreds of Indian patients with relapsed blood cancers, with published trial data showing meaningful, durable responses.
Who Is Eligible for CAR-T Therapy in India?
CAR-T therapy is not a first-line treatment. It is currently approved for patients who have already tried, and not responded adequately to, standard treatments. Broadly, NexCAR19 is approved for:
| Condition | Typical eligibility |
|---|---|
| Relapsed/refractory B-cell Acute Lymphoblastic Leukaemia (B-ALL) | Patients aged 15 years and above who have received at least two prior lines of therapy |
| Relapsed/refractory Large B-cell Lymphoma (LBCL), including DLBCL and transformed follicular lymphoma | Patients who have received at least two prior lines of therapy |
Your oncologist or haematologist will confirm eligibility based on your specific diagnosis, prior treatment history, organ function, and overall fitness for the procedure. If you or a family member has recently been told that chemotherapy or a stem cell transplant has not worked, it is worth specifically asking your treating doctor whether CAR-T therapy is an option. Our leukaemia and blood cancer guide explains how these cancers are diagnosed and staged in the first place.
What Does CAR-T Therapy Cost in India?
Cost is where NexCAR19 has changed the conversation entirely.
| Therapy | Approximate cost in India |
|---|---|
| NexCAR19 (indigenous) | ₹30–40 lakh |
| Imported CAR-T products (e.g., international brands administered in India) | ₹2.5–3.5 crore |
| CAR-T therapy in the United States | Upwards of $400,000 (roughly ₹3.3 crore+) |
This roughly tenfold reduction in cost compared to imported alternatives is what has made CAR-T therapy realistic for Indian middle-class families for the first time. That said, ₹30–40 lakh remains a very significant sum for most households, and patients should explore every available avenue for financial support before treatment begins.
Financial Support Options
- Ayushman Bharat PM-JAY and select state cancer schemes may cover portions of advanced cancer treatment at empanelled centres; coverage for CAR-T specifically is still evolving; check current empanelment status with your hospital's financial counsellor.
- Hospital-based charitable trusts and NGOs focused on cancer care often assist with partial funding.
- Crowdfunding platforms have helped many Indian families bridge funding gaps for advanced cancer therapies.
- Health insurance policies vary widely in whether they cover CAR-T therapy; check your policy's specific exclusions and sub-limits for cell and gene therapies before assuming coverage.
Which Hospitals Offer CAR-T Therapy in India?
As of 2026, CAR-T cell therapy is available at a growing network of tertiary cancer centres. ImmunoACT has established partnerships with over 130 hospitals, with active treatment currently delivered at more than 30 centres across over 10 cities, concentrated in Mumbai, Delhi NCR, Bengaluru, Chennai, Hyderabad, and Kolkata. Tata Memorial Hospital in Mumbai, as the original clinical development partner, remains one of the most experienced centres for this therapy. If you are considering CAR-T therapy, ask your current oncologist for a referral to the nearest centre offering it, since not every cancer hospital is currently certified to administer this therapy.
What to Expect: The Treatment Journey
Before Treatment
Your medical team will assess your overall fitness, organ function (particularly heart, lung, kidney, and liver function), and confirm that your cancer expresses the CD19 marker. T-cell collection (leukapheresis) typically takes a few hours and can usually be done as a day procedure.
Manufacturing Wait
Once collected, your T-cells are sent to the manufacturing facility for engineering and expansion. This process typically takes two to four weeks, during which some patients may need "bridging therapy" to keep their cancer under control.
Hospital Admission and Infusion
Patients are admitted to hospital for the conditioning chemotherapy and the CAR-T infusion itself. The infusion is usually quick, similar to a blood transfusion, but patients remain under close observation for one to two weeks afterward because side effects typically emerge in this window.
Side Effects to Know About
CAR-T therapy is generally well tolerated compared to intensive chemotherapy, but it carries two distinctive risks that Indian patients and families should understand before consenting to treatment:
- Cytokine Release Syndrome (CRS): As the engineered T-cells attack cancer cells, they release large amounts of inflammatory chemicals called cytokines. This can cause fever, low blood pressure, and breathing difficulty. Most cases are mild to moderate and manageable with supportive care and, in more severe cases, a specific antibody medication that blocks the inflammatory response.
- Neurotoxicity (ICANS): A smaller proportion of patients experience temporary confusion, difficulty speaking, or in rare severe cases, seizures. This is closely monitored and is usually reversible with prompt treatment.
Because of these risks, CAR-T therapy is administered only at certified centres with intensive care capability, and patients typically stay near the treatment centre for several weeks even after discharge.
Recovery and Follow-Up
Recovery timelines vary, but many patients see their blood counts and general strength improve over one to three months. Regular follow-up blood tests, imaging, and monitoring for late effects continue for months to years. Given how many reports a CAR-T patient accumulates, pre-treatment blood work, manufacturing confirmation reports, hospital discharge summaries, and follow-up scans, keeping them organised matters enormously. Families can upload every report to MedicalVault as it comes in, and use trend analysis to track blood counts and markers across the entire treatment journey in one place, which is especially useful when multiple specialists are involved in follow-up care.
How Effective Is CAR-T Therapy?
Clinical trial data presented for NexCAR19 showed that roughly two-thirds of treated patients had a meaningful reduction in their cancer, and about half achieved a complete response, meaning no detectable cancer on follow-up testing. For patients who have already failed multiple prior treatments, including a bone marrow transplant in some cases, these are considered strong results. It is important to have a realistic conversation with your treating haematologist about your individual chances of response, since outcomes vary by cancer type, prior treatment, and overall health.
Questions to Ask Your Oncologist
If CAR-T therapy is being considered for you or a family member, useful questions include:
- Does my specific cancer type and stage make me eligible for CAR-T therapy?
- Which centre near me is certified to administer NexCAR19 or another approved CAR-T product?
- What is the realistic cost, including hospital stay, monitoring, and any additional medications?
- Does my insurance policy or any government scheme cover part of this cost?
- What side effects should my family watch for after I am discharged?
- What does follow-up care look like over the next one to two years?
Key Takeaways
- CAR-T cell therapy re-engineers a patient's own immune cells to recognise and destroy cancer cells, and can offer durable remission for some blood cancers that have not responded to standard treatment.
- NexCAR19, developed by IIT Bombay-linked ImmunoACT and the Tata Memorial Centre, is India's first indigenous CAR-T therapy, priced at ₹30–40 lakh compared to ₹2.5–3.5 crore for imported alternatives.
- It is currently approved for relapsed or refractory B-cell ALL and large B-cell lymphoma in patients who have already tried at least two prior lines of treatment.
- Treatment involves collecting T-cells, two to four weeks of lab engineering, a short chemotherapy course, infusion, and close monitoring for cytokine release syndrome and neurotoxicity.
- The therapy is available at over 30 certified centres across more than 10 Indian cities, with Ayushman Bharat PM-JAY, hospital trusts, and NGOs offering partial financial support in some cases.
- Because CAR-T care generates many reports across a long treatment journey, keeping them organised with a tool like MedicalVault helps your care team track your progress accurately.
If you or a loved one has been told that standard treatment has not worked, ask your haematologist or oncologist directly whether CAR-T therapy is appropriate for your case. This is a rapidly evolving field, and eligibility criteria and available centres continue to expand each year.